z-logo
open-access-imgOpen Access
Drug Therapy of High-Risk Lipid Abnormalities in Children and Adolescents
Author(s) -
Brian W. McCrindle,
Elaine M. Urbina,
Barbara A. Dennison,
Mark Z. Jacobson,
Julia Steinberger,
Albert P. Rocchini,
Laura L. Hayman,
Stephen R. Daniels
Publication year - 2007
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/circulationaha.107.181946
Subject(s) - medicine , familial hypercholesterolemia , hyperlipidemia , drug , clinical trial , statin , pharmacotherapy , intensive care medicine , physical therapy , pediatrics , cholesterol , pharmacology , endocrinology , diabetes mellitus
Despite compliance with lifestyle recommendations, some children and adolescents with high-risk hyperlipidemia will require lipid-lowering drug therapy, particularly those with familial hypercholesterolemia. The purpose of this statement is to examine new evidence on the association of lipid abnormalities with early atherosclerosis, discuss challenges with previous guidelines, and highlight results of clinical trials with statin therapy in children and adolescents with familial hypercholesterolemia or severe hypercholesterolemia. Recommendations are provided to guide decision-making with regard to patient selection, initiation, monitoring, and maintenance of drug therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom